Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE‐JP Trial Authors: Koutaro Yokote, Toshimasa Yamauchi, Yasushi Fukushima, Yoji Takatsuka, Marie Kato, Shijia Yan, Takayoshi Inoue, Luiza Borowska, Martina Brueckmann, Wataru Ogawa, the SYNCHRONIZE‐JP Trial Investigators Published: 2026 ABSTRACT ABSTRACTAimsThere is an unmet need for effective pharmacotherapy for obesity disease management in Japan. Survodutide is a novel glucagon receptor/glucagon‐like peptide‐1 receptor (GLP‐1R) dual agonist with the potential to induce greater weight reductions than GLP‐1R mono‐agonists. We report the design and baseline participant characteristics of the SYNCHRONIZE‐JP trial evaluating survodutide in Japanese adults with obesity disease (ClinicalTrials.gov: NCT06176365).Materials and MethodsSYNCHRONIZE‐JP is a 76‐week, randomised, double‐blind, parallel‐group, multi‐centre, phase 3 clinical trial. Eligible participants were aged ≥ 18 years, with BMI ≥ 35 kg/m2 with ≥ 1 obesity complication or BMI ≥ 27 kg/m2 with ≥ 2 obesity complications, ≥ 1 self‐reported unsuccessful dietary effort to lose body weight and ≥ 1 obesity complication required to be type 2 diabetes (T2D; capped at 30% enrolment), hypertension or dyslipidaemia. Participants were randomised 1:1:1 to receive once‐weekly survodutide 3.6 or 6.0 mg, or placebo, accompanied by a reduced‐calorie diet and increased physical activity. The primary endpoints are percentage change in body weight and achievement of body weight reduction ≥ 5% from baseline to Week 76. A subset of participants will be assessed for additional endpoints of liver fat content and body composition.ResultsOf 274 enrolled participants, 24.1% had T2D. The mean age was 53.1 years; 47.8% were female, and mean BMI was 33.2 kg/m2. The most frequent complications were dyslipidaemia (81.4%), hypertension (72.6%), hyperuricaemia (30.3%) and metabolic dysfunction‐associated steatotic liver disease (26.6%).ConclusionsThe results of SYNCHRONIZE‐JP will provide Japan‐specific efficacy, safety and tolerability data for survodutide and inform its potential role in the management of obesity disease.Keywords: glucagon receptor agonist, glucagon‐like peptide‐1 receptor agonist, obesity, survodutide, trial design Introduction Obesity is a complex, heterogenous disease, affecting ~16% of adults globally [1]. Although reported rates of obesity are highest in Europe (20.0%) and the Americas (22.4%), there has been a notable increase in the prevalence of overweight and obesity in East Asian countries [2, 3, 4]. In Japan, approximately 3.6% (~2 million) women and 7.6% (~3.2 million) men had a body mass index (BMI) of ≥ 30 kg/m2 in 2022, an increase of 1.4% and 6.1%, respectively, from 1990 [5]. This growing prevalence of overweight and obesity in Japan is associated with an increasing humanistic and economic burden, with the total economic burden of overweight and obesity estimated at 13.4 billion USD in 2023 [4, 6, 7, 8]. The risk for obesity complications, such as type 2 diabetes (T2D) and metabolic dysfunction–associated steatotic liver disease (MASLD), or its more severe form metabolic dysfunction–associated steatohepatitis (MASH), appears to be higher at lower BMIs among people in Japan and other East Asian countries compared with Western populations, potentially because of a greater relative accumulation of visceral fat [9, 10, 11, 12, 13]. Consequently, obesity is defined in the Japan Society for the Study of Obesity (JASSO) guidelines for obesity management as a BMI of ≥ 25 kg/m2 [10, 14], lower than the ≥ 30 kg/m2 threshold in Western countries [15, 16, 17, 18, 19]. Approximately 33.0% of adult men and 22.3% of adult women in Japan met this definition of obesity in 2020 [5, 20]. The JASSO guidelines also delineate the concepts of ‘obesity disease’ (BMI ≥ 25 kg/m2 with obesity complications), ‘high‐degree obesity’ (BMI ≥ 35 kg/m2) and ‘high‐degree obesity disease’ (BMI ≥ 35 kg/m2 with obesity complications), where the designation of ‘disease’ denotes conditions that medically require weight reduction [10, 14]. The JASSO guidelines recommend pharmacotherapy for people with non‐responsive high‐degree obesity disease or obesity disease with ≥ 2 obesity complications [10, 14]. Currently, approved pharmacologic therapies for chronic obesity management in Japan are limited. These include mazindol [21], the lipase inhibitor orlistat, the glucagon‐like peptide‐1 (GLP‐1) receptor agonist semaglutide, and the glucose‐dependent insulinotropic polypeptide receptor and GLP‐1 receptor dual agonist tirzepatide. Semaglutide and tirzepatide were approved in Japan in 2023 and 2024, respectively, for patients with obesity disease with either a BMI ≥ 35 kg/m2 with ≥ 1 obesity complication or BMI ≥ 27 kg/m2 with ≥ 2 obesity complications, who have not responded adequately to dietary and exercise therapy and have ≥ 1 complication of T2D, hypertension, or dyslipidaemia [22, 23]. Survodutide is a novel, long‐acting dual agonist of both the glucagon and GLP‐1 receptors that is being investigated for the treatment of obesity and MASH [24, 25, 26, 27]. Dual activation of the glucagon receptor and GLP‐1 receptor signalling pathways is hypothesised to have multiple clinical benefits for people with obesity, attributed to the synergistic reduction in energy intake achieved with GLP‐1 receptor agonists and the metabolic effects of glucagon that result in greater energy expenditure and reduced liver fat content [28, 29]. In a recent phase 2 trial conducted in 387 participants with BMI ≥ 27 kg/m2 without T2D (of whom 10% were non‐Japanese Asian), survodutide was associated with dose‐dependent reductions in body weight of up to 14.9%, versus 2.8% with placebo [24]. In a phase 2 trial evaluating participants with T2D, treatment with survodutide over 16 weeks was associated with dose‐dependent reductions in glycated haemoglobin (HbA1c) levels, where the mean absolute change in HbA1c observed in the low‐dose survodutide group (0.9 mg) was comparable to that observed with semaglutide 1.0 mg (−15.95 mmol/mol [−1.46%] vs. −16.07 mmol/mol [−1.47%], respectively) [30]. Survodutide is being evaluated in SYNCHRONIZE, a comprehensive multinational phase 3 clinical development programme for the treatment of obesity. SYNCHRONIZE‐1 (individuals without T2D) and SYNCHRONIZE‐2 (individuals with T2D) [31, 32, 33], as well as the SYNCHRONIZE‐JP [34] and SYNCHRONIZE‐CN [35] trials in Japan and China, respectively, will build upon the efficacy and safety findings of preceding phase 2 trials to evaluate survodutide as a treatment for overweight and obesity. The SYNCHRONIZE‐CVOT [36, 37] and SYNCHRONIZE‐MASLD [38] trials will further assess the efficacy and safety of survodutide in people with overweight and obesity and with increased cardiovascular risk, and confirmed or presumed MASH, respectively. SYNCHRONIZE‐JP will fulfil an unmet need for Japan‐specific data on survodutide. Japanese individuals did not participate in the phase 2 trial of survodutide in overweight and obesity, and the data on the efficacy, safety, and appropriate dosage of survodutide in people who meet the diagnostic criteria for obesity disease were insufficient. Here, we report the rationale, design and blinded baseline characteristics of SYNCHRONIZE‐JP, a phase 3 trial that evaluates the efficacy, safety and tolerability of survodutide in people with obesity disease or high‐degree obesity disease in Japan [10, 14]. Materials and Methods Overall Trial Design SYNCHRONIZE‐JP (clinicaltrials.gov: NCT06176365, registered 19 December 2023) [34] is a 76‐week, randomised, double‐blind, parallel‐group, three‐arm, multi‐centre, phase 3 clinical trial evaluating the efficacy, safety and tolerability of once‐weekly survodutide versus placebo. The trial is being conducted at 28 clinical sites in Japan. The trial includes a substudy evaluating changes in body composition via magnetic resonance imaging (MRI), and liver fat content by MRI‐proton density fat fraction (PDFF) in a subset of trial participants before randomisation and at Week 76. Participation in the MRI assessments is voluntary, with separate informed consent. The trial protocol was approved by institutional review boards and/or independent ethics committees at each site, according to national and international regulations. The trial is being conducted according to the Declaration of Helsinki, the International Council for Harmonisation (ICH) harmonised tripartite guideline for Good Clinical Practice (GCP), the Japanese GCP and other relevant regulations. All participants provided written informed consent before entering the trial in accordance with the ICH and Japanese GCP, and informed consent forms were retained by the study investigators as part of the trial records. Participants Key inclusion and exclusion criteria are summarised in Table 1; full eligibility criteria are provided in Data S1: methods A. Eligible participants included male or female individuals aged ≥ 18 years, who had a BMI ≥ 35 kg/m2 with ≥ 1 obesity complication, or BMI ≥ 27 kg/m2 with ≥ 2 obesity complications according to JASSO guidelines [10, 14]. At least one obesity complication was required to be T2D, hypertension or dyslipidaemia. Participants also had to have a history of ≥ 1 self‐reported unsuccessful dietary effort to lose body weight. Key exclusion criteria included a body weight change of > 5% or treatment with any obesity management medication (OMM) < 3 months before screening, previous or planned surgical treatment for obesity, or obesity induced by other endocrinologic disorders or diagnosed monogenic or syndromic forms of obesity. In addition to OMMs, the use of any T2D medication not explicitly permitted per the inclusion criteria, as well as any medication which may cause changes to body weight, was prohibited from 3 months prior to screening through the duration of the trial; a complete listing of prohibited treatments is provided in Data S1. The MRI substudy was conducted at eligible sites that expressed interest in participation and met the standards for site qualification, including imaging protocol and image quality. Subjects who provided informed consent at these sites were enrolled in the substudy. Participants were included if at least one baseline MRI scan met acceptable quality standards by the imaging laboratory prior to randomisation. TABLE 1Key eligibility criteria for the SYNCHRONIZE‐JP trial.SYNCHRONIZE‐JPKey inclusion criteriaMale or female, age ≥ 18 yearsBMI ≥ 35 kg/m2 with ≥ 1 obesity complication a or BMI ≥ 27 kg/m2 with ≥ 2 obesity complications a , b . For all trial participants, ≥ 1 comorbidity should be T2D, hypertension or dyslipidaemia≥ 1 self‐reported unsuccessful dietary effort to lose body weight For the subset of participants with MRI assessment of body composition and MRI‐PDFF assessment of liver fat: Acceptable quality of the baseline scan as defined by the imaging laboratory before randomisationKey exclusion criteriaObesity‐relatedSelf‐reported change in body weight > 5% within 3 months before screeningTreatment with any medication for the indication obesity within 3 months before screeningPrevious or planned (during the trial period) treatment for obesity with surgery or a weight loss device, or prior surgery of the gastrointestinal tract that could interfere with body weightObesity induced by other endocrinologic disorders or monogenetic or syndromic forms of obesityGlycaemia‐related For trial participants without T2D: History of T1D or T2D or treatment with glucose‐lowering agent started within 3 months before screening For trial participants with T2D: Treatment with any medication for the indication of T2D other than stated in the inclusion criteria within 3 months before screening (i.e., insulin, amylin analogues, GLP‐1 receptor agonists, GLP‐1 receptor agonist/insulin/GIP combinations and DPP‐4i)New initiation of any other glucose‐lowering investigational drug within 3 months before screening for this trialUncontrolled and potentially unstable diabetic retinopathy or maculopathy, verified by an eye examination within 3 months before screening or between screening and randomisationMental healthAnswered ‘yes’ to any of the suicide‐related behaviours or to the non‐suicidal self‐injurious behaviour questions, relating to the past 2 years or during screening; or suicidal ideation relating to the past 3 months or during screeningSignificant active or unstable major depressive disorder or other severe psychiatric disorder within the last 2 years before screening, or major depressive symptoms (PHQ‐9 score ≥ 15) at screening or during the screening period c MedicalTreatment with medications which may cause significant weight change started within 3 months before screeningImpaired renal function, defined as eGFR < 30 mL/min/1.73 m2 (CKD‐EPIcr) at screening or requiring dialysisKnown clinically significant gastric emptying abnormalityUncontrolled hypo‐ or hyperthyroidism at screeningHistory of chronic or acute pancreatitis or elevation of serum lipase or amylase > 2× ULN at screeningUncontrolled hypertension (mean SBP ≥ 160 mmHg and/or mean DBP ≥ 100 mmHg) at screeningRecent evidence (within 3 months before screening) of acute or unstable cardiovascular events and/or acute peripheral vascular eventHeart failure with NYHA functional class IVQTc (Fridericia) mean interval > 500 ms at screening (triplicate electrocardiogram) or personal/family history of long QT syndromeSerum AST and/or ALT elevation ≥ 3× ULN or total serum bilirubin concentration ≥ 1.2× ULNHistory or evidence of chronic liver disease other than MASLD, including ongoing active or chronic viral hepatitisHistory of infection with HIV or positive HIV test at screeningMajor surgery within 3 months before screening or planned during the trialPersonal or family history of medullary thyroid carcinoma or MEN 2Calcitonin ≥ 100 pg/mL (≥ 29.26 pmol/L)Confirmed diagnosis of malignancy within 5 years before screening (except for basal or squamous‐cell carcinoma of the skin that has been treated successfully)History of organ transplantation or awaiting an organ transplantHaematological condition that may interfere with HbA1c measurement at screeningWomen who are pregnant, nursing or who plan to become pregnant while in the trialKnown or suspected hypersensitivity to the IMP or related productsAbbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CKD‐EPIcr, Chronic Kidney Disease Epidemiology Collaboration creatinine equation; CVD, cardiovascular disease; DBP, diastolic blood pressure; DPP‐4i, dipeptidyl peptidase‐4 inhibitor; eGFR, estimated glomerular filtration rate; GIP, glucose‐dependent insulinotropic polypeptide; GLP‐1, glucagon‐like peptide‐1; HbA1c, glycated haemoglobin; IMP, investigational medicinal product; JASSO, Japan Society for the Study of Obesity; MASH, metabolic dysfunction‐associated steatohepatitis; MASLD, metabolic dysfunction–associated steatotic liver disease; MEN 2, multiple endocrine neoplasia syndrome type 2; MRI, magnetic resonance imaging; MRI‐PDFF, magnetic resonance imaging‐proton density fat fraction; NYHA, New York Heart Association; PHQ‐9, Patient Health Questionnaire‐9; QTc, QT interval corrected for heart rate; SBP, systolic blood pressure; T1D, type 1 diabetes; T2D, type 2 diabetes; ULN, upper limit of normal. a Obesity‐related health disorders defined according to JASSO guidelines [10, 14]: glucose intolerance (T2D, impaired glucose tolerance, etc.), dyslipidaemia, hypertension, hyperuricaemia/gout, coronary artery disease, cerebral infarction/transient ischaemic attack, non‐alcoholic fatty liver disease, menstrual disorder/female infertility, obstructive sleep apnoea syndrome/obesity‐hypoventilation syndrome, motor system disorders, obesity‐related kidney disease. b For comparison, SYNCHRONIZE‐1: BMI ≥ 30 or BMI ≥ 27 kg/m2 and ≥ 1 weight‐related comorbidity (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, CVD, MASH), without T2D; SYNCHRONIZE‐2: BMI ≥ 27 kg/m2 with T2D [31]. c For comparison, SYNCHRONIZE‐1 and ‐2: Reported a history of psychiatric inpatient hospitalisation within the past year before screening, or are not stabilised on psychiatric medication, or major depressive symptoms (PHQ‐9 score ≥ 15) at screening or during the screening period [31]. Key eligibility criteria for the SYNCHRONIZE‐JP trial. Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CKD‐EPIcr, Chronic Kidney Disease Epidemiology Collaboration creatinine equation; CVD, cardiovascular disease; DBP, diastolic blood pressure; DPP‐4i, dipeptidyl peptidase‐4 inhibitor; eGFR, estimated glomerular filtration rate; GIP, glucose‐dependent insulinotropic polypeptide; GLP‐1, glucagon‐like peptide‐1; HbA1c, glycated haemoglobin; IMP, investigational medicinal product; JASSO, Japan Society for the Study of Obesity; MASH, metabolic dysfunction‐associated steatohepatitis; MASLD, metabolic dysfunction–associated steatotic liver disease; MEN 2, multiple endocrine neoplasia syndrome type 2; MRI, magnetic resonance imaging; MRI‐PDFF, magnetic resonance imaging‐proton density fat fraction; NYHA, New York Heart Association; PHQ‐9, Patient Health Questionnaire‐9; QTc, QT interval corrected for heart rate; SBP, systolic blood pressure; T1D, type 1 diabetes; T2D, type 2 diabetes; ULN, upper limit of normal. Obesity‐related health disorders defined according to JASSO guidelines [10, 14]: glucose intolerance (T2D, impaired glucose tolerance, etc.), dyslipidaemia, hypertension, hyperuricaemia/gout, coronary artery disease, cerebral infarction/transient ischaemic attack, non‐alcoholic fatty liver disease, menstrual disorder/female infertility, obstructive sleep apnoea syndrome/obesity‐hypoventilation syndrome, motor system disorders, obesity‐related kidney disease. For comparison, SYNCHRONIZE‐1: BMI ≥ 30 or BMI ≥ 27 kg/m2 and ≥ 1 weight‐related comorbidity (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, CVD, MASH), without T2D; SYNCHRONIZE‐2: BMI ≥ 27 kg/m2 with T2D [31]. For comparison, SYNCHRONIZE‐1 and ‐2: Reported a history of psychiatric inpatient hospitalisation within the past year before screening, or are not stabilised on psychiatric medication, or major depressive symptoms (PHQ‐9 score ≥ 15) at screening or during the screening period [31]. Randomisation, Treatment and Assessments Eligible participants were randomised 1:1:1 to once‐weekly subcutaneous injections of survodutide 3.6 or 6.0 mg or placebo as an adjunct to a reduced‐calorie diet and increased physical activity (Data S1). Randomisation was arranged by the study sponsor and was implemented in blocks using equal allocations to each double‐blind treatment group by a computer‐generated random sequence using an interactive response system and stratified according to baseline status of T2D (yes/no) and sex (male/female). Enrolment of participants with T2D was capped at 30% in each arm. Survodutide doses are up‐titrated to 3.6 or 6.0 mg during an initial dose‐escalation period of 24 weeks that may be extended if one or two re‐escalation attempts are needed because of gastrointestinal symptoms. Following dose‐escalation, participants enter a dose maintenance period of up to 52 weeks. Participants are assessed on site or remotely every 2–4 weeks during the dose‐escalation period and every 6 weeks during the maintenance period until the end of treatment at Week 76, with a follow‐up end‐of‐study visit 21 days after the end‐of‐treatment visit. Participants, investigators and all other individuals involved in trial conduct are blinded to treatment assignment. At randomisation and all in‐clinic visits, participants will receive counselling with regard to diet (recommended energy deficit of ~500 kcal per day) and physical activity (recommended minimum 150 min per week). Participants included in the body composition substudy have MRI and MRI‐PDFF assessments before randomisation and at Week 76. MRIs were conducted at qualifying imaging sites with support from Antaros Medical (Mölndal, Sweden), which implemented a standardised imaging protocol during the trial to ensure consistency and reliability of the imaging data. The protocol was detailed in a dedicated trial imaging manual designed to harmonise the MRI scanning procedures for body composition across all sites and required a healthy volunteer scan at each site to qualify the implemented imaging protocol and ensure proper setup and calibration of the scanners. Comprehensive training for all sites was conducted by Antaros to ensure adherence to the standardised imaging protocol to minimise variability and produce high‐quality imaging data across participating sites. The imaging data were evaluated by an independent central review performed by Antaros and guided by a dedicated Imaging Charter, which outlined the procedures for the central read to ensure consistency and rigour in the evaluation process, as well as comprehensive quality control measures and rigorous MRI assessments to ensure the accuracy and reliability of the data. Endpoints Co‐primary and secondary endpoints—and additional endpoints assessed in a subset of participants by MRI—are summarised in Table 2. The primary endpoints are the percentage change in body weight and achievement of body weight reduction ≥ 5% from baseline to Week 76. The secondary endpoints, also evaluated as change from baseline to Week 76, are the achievement of body weight reduction ≥ 10%, ≥ 15% and ≥ 20%, and the absolute change in body weight, BMI, waist circumference, systolic blood pressure, diastolic blood pressure, ‘Capacity to resist’ domain score and total score of the Eating Behaviour Patient‐Reported Outcome [39], HbA1c, fasting plasma glucose, fasting plasma insulin, total cholesterol, high‐density lipoprotein, low‐density lipoprotein, very‐low‐density lipoprotein, triglycerides, free fatty acids, alanine aminotransferase and aspartate aminotransferase. Additional endpoints will be assessed from baseline to Week 76 in a subset of participants by MRI, including the relative change in liver fat content (%) as assessed by MRI‐PDFF, and the absolute and relative change in total fat volume, lean body volume, visceral fat volume, subcutaneous fat volume and contractile thigh muscle volume, as assessed by MRI. Further efficacy, safety, pharmacokinetic, biomarker and immunogenicity endpoints are detailed in Data S1: methods B. TABLE 2Primary and secondary endpoints of the SYNCHRONIZE‐JP trial.Endpoints from baseline to Week 76Primary endpointsPercentage change in body weightAchievement of body weight reduction ≥ 5%Secondary endpointsAchievement of body weight reduction ≥ 10%, ≥ 15%, ≥ 20%Absolute change in:Body weight (kg)BMI (kg/m2)Waist circumference measured at umbilical level (cm) a Waist circumference measured between the lower rib margin and iliac crest (cm)SBP (mmHg)DBP (mmHg)‘Capacity to resist’ domain score of the EB PRO measureEB PRO total score [39]HbA1c (%, mmol/mol) b FPG (mg/dL)FPI (mIU/L)Total cholesterol (mg/dL)HDL (mg/dL)LDL (mg/dL)VLDL (mg/dL)Triglycerides (mg/dL)Free fatty acids (mg/dL)ALT (U/L)AST (U/L)Additional secondary endpoints c Relative change in liver fat content (%), assessed by MRI‐PDFFRelative and absolute change in d :Total fat volume (percentage [%], volume [L])Lean body volume (percentage [%], volume [L])Visceral fat volume (percentage [%], volume [L])Subcutaneous fat volume (percentage [%], volume [L])Contractile thigh muscle volume (percentage [%], volume [L])Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; DBP, diastolic blood pressure; EB PRO, Eating Behaviour Patient‐Reported Outcome; FPG, fasting plasma glucose; FPI, fasting plasma insulin; HbA1c, glycated haemoglobin; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; MRI, magnetic resonance imaging; MRI‐PDFF, magnetic resonance imaging‐proton density fat fraction; SBP, systolic blood pressure; VLDL, very low‐density lipoprotein. a For comparison, in SYNCHRONIZE‐1 and ‐2, waist circumference was measured between the lower rib margin and iliac crest only. b For comparison, HbA1c was measured as a secondary endpoint (% and mmol/mol) in SYNCHRONIZE‐1 and as a key secondary endpoint (%) as well as secondary endpoint (mmol/mol) in SYNCHRONIZE‐2 [31]. c To be assessed by MRI in a subset of participants. d For comparison, SYNCHRONIZE‐1 will measure absolute change in total fat volume (% and L), lean body volume (% and L), visceral fat volume (% and L) and subcutaneous fat volume (% and L); contractile thigh muscle volume is not being assessed [31]. Primary and secondary endpoints of the SYNCHRONIZE‐JP trial. Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; DBP, diastolic blood pressure; EB PRO, Eating Behaviour Patient‐Reported Outcome; FPG, fasting plasma glucose; FPI, fasting plasma insulin; HbA1c, glycated haemoglobin; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; MRI, magnetic resonance imaging; MRI‐PDFF, magnetic resonance imaging‐proton density fat fraction; SBP, systolic blood pressure; VLDL, very low‐density lipoprotein. For comparison, in SYNCHRONIZE‐1 and ‐2, waist circumference was measured between the lower rib margin and iliac crest only. For comparison, HbA1c was measured as a secondary endpoint (% and mmol/mol) in SYNCHRONIZE‐1 and as a key secondary endpoint (%) as well as secondary endpoint (mmol/mol) in SYNCHRONIZE‐2 [31]. To be assessed by MRI in a subset of participants. For comparison, SYNCHRONIZE‐1 will measure absolute change in total fat volume (% and L), lean body volume (% and L), visceral fat volume (% and L) and subcutaneous fat volume (% and L); contractile thigh muscle volume is not being assessed [31]. Safety and tolerability are assessed through adverse event (AE) reporting, including serious AEs, AEs of special interest, and monitoring of vital signs, electrocardiogram, physical examination and laboratory test results. Pre‐specified AEs of special interest include potential severe drug‐induced liver injury, thyroid malignancies, C‐cell hyperplasia, systemic and serious cutaneous hypersensitivity or anaphylactic reactions, acute gallbladder disease and severe hypoglycaemia requiring assistance (in participants with T2D at baseline). Study Oversight and Organisation This trial is sponsored by Boehringer Ingelheim and was designed with the advice of Japanese experts. An independent data‐monitoring committee regularly reviews safety data (including an unblinded safety assessment at specified intervals) and recommends continuation, modification, or termination of the trial. An independent, blinded clinical event committee prospectively adjudicates major adverse cardiovascular events, non‐cardiovascular death, heart failure events, hospitalisation for coronary artery revascularisation or for unstable angina leading to coronary artery revascularisation, pancreatitis, and thyroid and pancreatic cancer. Statistical Analysis Statistical analyses are based on the randomised set (all randomised participants) and the treated set (all randomised participants who received ≥ 1 dose of study drug). It was planned to randomise 240 participants (80 per arm), which would provide 99.5% statistical power for the two co‐primary endpoints, tested in a pre‐specified graphical approach with a two‐sided α of 0.05 for each dose group. For the body composition substudy, it was estimated that approximately 80 trial participants (across the treatment and placebo arms) would be eligible and consent to inclusion. Efficacy will be assessed based on a treatment regimen estimand, which will take into account the effect of any early discontinuation, prohibited OMM, or prolonged dose‐escalation phase, as well as an efficacy estimand, which will estimate the treatment effect if all trial participants had adhered to treatment, had not received any prohibited OMM, and includes the effect of any prolonged dose‐escalation phase. For the treatment regimen estimand, missing body weight data after early treatment discontinuation will be multiple‐imputed by a retrieved‐dropout approach, with a missing not at random (MNAR) assumption. If there are not enough retrieved dropouts to provide a reliable imputation model, multiple imputation will be based solely on the placebo arm applying a ‘follow the reference’ strategy. Data for the continuous primary endpoint of percentage change in body weight will be analysed using analysis of covariance with treatment, baseline T2D status (yes/no) and sex (male/female) as fixed effects; baseline outcome value will be treated as a covariate. For the efficacy estimand, a mixed model for repeated measures will be used for analysis with fixed effects for baseline outcome value as a continuous linear covariate; treatment, baseline T2D status (yes/no), sex (male/female), visit, treatment by visit interaction and baseline outcome value by visit interaction treated as factors, with participant treated as a random effect. An unstructured covariance matrix will be used to model within‐participant measurements. The missing data will be handled in an implicit way. For the binary primary endpoint, achievement of body weight reduction ≥ 5% from baseline to Week 76 will be obtained from the imputed data set under treatment regimen estimand or by a multiple imputation approach based on a missing at random (MAR) assumption for the efficacy estimand. Comparisons between active and placebo treatment will be conducted using a logistic regression with fixed categorical effects of treatment, baseline T2D status (yes/no) and sex (male/female), with the baseline outcome value treated as a continuous linear covariate. For each endpoint, results obtained from multiple imputation runs will be summarised into a single estimate for the respective treatment effect. A multiple testing procedure for the primary endpoints will be implemented using a graphical approach that controls the familywise error rate within each estimand at an overall two‐sided α of 5%. Descriptive statistics are summarised for baseline characteristics and demographic data. The safety analyses will be descriptive in nature and no hypothesis testing is planned. Results Trial Status Recruitment of participants began on 16 January 2024, with 274 participants enrolled from 28 study sites in Japan [34]. Baseline Characteristics The mean age of participants was 53.1 years, mean body weight was 90.7 kg, mean BMI was 33.2 kg/m2 and 47.8% were female (Table 3). The non‐T2D subgroup had a greater proportion of female participants than the T2D subgroup (51.9% vs. 34.8%). Among the non‐T2D subgroup, 29.3% and 38.5% had a BMI ≥ 27 to < 30 and ≥ 30 to < 35, compared with 42.4% and 31.8% in the T2D subgroup, respectively. TABLE 3Demographic and clinical characteristics of participants at baseline. a CharacteristicsNon‐T2D (n = 208)T2D (n = 66)MRI subset (n = 81)Total (n = 274)Age, years52.2 ± 11.056.1 ± 9.2 54.4 ± 9.2 53.1 ± 10.7Female, n (%)108 (51.9)23 (34.8) 33 (40.7) 131 (47.8)Body weight (kg)90.6 ± 16.291.0 ± 17.7 89.8 ± 15.0 90.7 ± 16.5BMI (kg/m2 ) 33.4 ± 4.932.6 ± 5.2 32.2 ± 4.2 33.2 ± 5.0BMI group, n (%)≥ 27 to < 3061 (29.3)28 (42.4) 32 (39.5) 89 (32.5)≥ 30 to < 3580 (38.5)21 (31.8) 27 (33.3) 101 (36.9)≥ 35 to < 4045 (21.6)12 (18.2) 19 (23.5) 57 (20.8)≥ 4022 (10.6)5 (7.6) 3 (3.7) 27 (9.9)Waist circumference (cm)Umbilical level107.6 ± 12.4107.7 ± 12.9 105.7 ± 12.1 107.6 ± 12.5Between lower rib margin and iliac crest104.5 ± 11.7106.2 ± 12.4 104.3 ± 11.3 104.9 ± 11.9Blood pressure (mmHg)Systolic128.2 ± 12.7127.8 ± 17.1 126.6 ± 13.2 128.1 ± 13.9Diastolic81.4 ± 9.879.7 ± 12.4 79.4 ± 10.1 81.0 ± 10.5Heart rate (bpm)65.6 ± 10.866.7 ± 8.7 66.0 ± 8.9 65.9 ± 10.3Lipid levels (mg/dL)Total cholesterol212.5 ± 34.8199.9 ± 31.0 211.0 ± 27.8 209.4 ± 34.3HDL cholesterol56.6 ± 13.353.7 ± 10.3 55.6 ± 11.7 55.9 ± 12.7LDL cholesterol126.3 ± 31.3114.3 ± 24.6 126.0 ± 25.0 123.4 ± 30.2VLDL cholesterol28.9 ± 12.930.4 ± 13.2 29.1 ± 12.9 29.2 ± 12.9Triglycerides152.6 ± 112.3160.6 ± 100.9 146.7 ± 68.3 154.6 ± 109.5Estimated GFR (mL/min/1.73 m2)74.2 ± 13.875.8 ± 12.9 73.8 ± 12.7 74.6 ± 13.6Uric acid (mg/dL)5.9 ± 1.35.3 ± 1.2 5.8 ± 1.2 5.8 ± 1.3HbA1c (%)5.7 ± 0.47.5 ± 0.9 6.4 ± 1.1 6.1 ± 1.0FPG (mg/dL)100.4 ± 11.0144.3 ± 27.3 120.3 ± 27.4 111.1 ± 25.1FPI (mIU/L)9.4 ± 5.99.5 ± 6.3 9.8 ± 5.8 9.4 ± 6.0HOMA‐IR2.4 ± 1.73.4 ± 2.5 3.0 ± 2.0 2.6 ± 2.0HOMA‐β92.0 ± 51.845.6 ± 30.1 72.8 ± 46.3 80.7 ± 51.4Free fatty acid (mg/dL)11.2 ± 4.211.9 ± 4.8 9.9 ± 3.6 11.4 ± 4.4AST (U/L)27.3 ± 14.026.1 ± 11.0 28.7 ± 13.5 27.0 ± 13.3ALT (U/L)34.1 ± 22.832.7 ± 21.0 37.2 ± 23.0 33.7 ± 22.4Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; bpm, beats per minute; FPG, fasting plasma glucose; FPI, fasting plasma insulin; GFR, glomerular filtration rate; HbA1c, glycated haemoglobin; HDL, high‐density lipoprotein; HOMA‐β, homeostasis model assessment of β‐cell function; HOMA‐IR, homeostasis model assessment of insulin resistance; LDL, low‐density lipoprotein; MRI, magnetic resonance imaging; T2D, type 2 diabetes; VLDL, very low‐density lipoprotein. a Plus–minus values denote mean ± standard deviation. Demographic and clinical characteristics of participants at baseline. a Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; bpm, beats per minute; FPG, fasting plasma glucose; FPI, fasting plasma insulin; GFR, glomerular filtration rate; HbA1c, glycated haemoglobin; HDL, high‐density lipoprotein; HOMA‐β, homeostasis model assessment of β‐cell function; HOMA‐IR, homeostasis model assessment of insulin resistance; LDL, low‐density lipoprotein; MRI, magnetic resonance imaging; T2D, type 2 diabetes; VLDL, very low‐density lipoprotein. Plus–minus values denote mean ± standard deviation. The most frequent obesity complications were dyslipidaemia (81.4%), hypertension (72.6%), hyperuricaemia (30.3%) and MASLD (26.6%) (Table 4). A greater proportion of participants without T2D versus with T2D, had hyperuricaemia (32.7% vs. 22.7%), obstructive sleep apnoea syndrome (20.7% vs. 15.2%), osteoarthritis (17.3% vs. 7.6%), menstrual disorder (6.7% vs. 3.0%) and obesity‐related kidney disease (5.3% vs. 1.5%). Among participants in the MRI and MRI‐PDFF substudy, liver fat content (12.1% vs. 14.3%) and visceral fat volume (5.3 L vs. 6.6 L) tended to be higher in the T2D group, whereas other body composition parameters were similar between groups (Table 5). TABLE 4Obesity complications in participants at baseline.Obesity complication, n (%)Non‐T2D (n = 208)T2D (n = 66)MRI subset (n = 81)Overall (n = 274)Dyslipidaemia169 (81.3)54 (81.8) 72 (88.9) 223 (81.4)Hypertension152 (73.1)47 (71.2) 59 (72.8) 199 (72.6)Hyperuricaemia68 (32.7)15 (22.7) 29 (35.8) 83 (30.3)MASLD55 (26.4)18 (27.3) 27 (33.3) 73 (26.6)T2D0 (0)66 (100) 29 (35.8) 66 (24.1)Obstructive sleep apnoea syndrome43 (20.7)10 (15.2) 10 (12.3) 53 (19.3)Osteoarthritis36 (17.3)5 (7.6) 8 (9.9) 41 (15.0)Glucose intolerance excluding T2D19 (9.1)0 (0) 7 (8.6) 19 (6.9)Menstrual disorder14 (6.7)2 (3.0) 1 (1.2) 16 (5.8)Obesity‐related kidney disease11 (5.3)1 (1.5) 3 (3.7) 12 (4.4)Motor system disorder9 (4.3)2 (3.0) 1 (1.2) 11 (4.0)Obesity‐hypoventilation syndrome5 (2.4)2 (3.0) 0 (0) 7 (2.6)Spondylosis deformans6 (2.9)1 (1.5) 0 (0) 7 (2.6)Gout4 (1.9)1 (1.5) 4 (4.9) 5 (1.8)Coronary artery disease4 (1.9)0 (0) 1 (1.2) 4 (1.5)Cerebral infarction2 (1.0)1 (1.5) 0 (0) 3 (1.1)Female infertility2 (1.0)0 (0) 0 (0) 2 (0.7)Transient ischaemic attack0 (0)1 (1.5) 0 (0) 1 (0.4)Abbreviations: MASLD, metabolic dysfunction‐associated steatotic liver disease; MRI, magnetic resonance imaging; T2D, type 2 diabetes. Obesity complications in participants at baseline. Abbreviations: MASLD, metabolic dysfunction‐associated steatotic liver disease; MRI, magnetic resonance imaging; T2D, type 2 diabetes. TABLE 5Baseline liver fat content and body composition characteristics of participants assessed by MRI and MRI‐PDFF. a CharacteristicsNon‐T2D (n = 52)T2D (n = 29)Total (n = 81)Liver fat content (%)12.1 ± 8.614.3 ± 6.912.9 ± 8.1Total fat volume (L)27.0 ± 7.127.4 ± 8.527.1 ± 7.6Lean body volume (L)24.0 ± 4.726.0 ± 5.224.7 ± 5.0Visceral fat volume (L)5.3 ± 1.86.6 ± 2.55.8 ± 2.2Subcutaneous fat volume (L)18.1 ± 6.716.9 ± 7.517.7 ± 7.0Contractile thigh muscle volume (L)6.5 ± 1.66.9 ± 1.56.6 ± 1.6Abbreviations: MRI, magnetic resonance imaging; MRI‐PDFF, magnetic resonance imaging‐proton density fat fraction; T2D, type 2 diabetes. a Plus–minus values denote mean ± standard deviation. Baseline liver fat content and body composition characteristics of participants assessed by MRI and MRI‐PDFF. a Abbreviations: MRI, magnetic resonance imaging; MRI‐PDFF, magnetic resonance imaging‐proton density fat fraction; T2D, type 2 diabetes. Plus–minus values denote mean ± standard deviation. Discussion This 76‐week, randomised, double‐blind, multi‐centre, phase 3 clinical trial will investigate the efficacy, safety and tolerability of survodutide in Japanese participants with obesity disease. The risk for obesity complications increases with increasing BMI, and a weight reduction of 5%–10% has demonstrated significant health benefits by slowing progression to T2D and improving obesity complications, physical functioning and quality of life. In people with T2D and obesity, sustained weight reduction may have a beneficial impact on cardiovascular risk and mortality [15]. American and European clinical guidelines recommend medical treatment for weight reduction in people with obesity and a BMI ≥ 30 kg/m2 and people who are overweight with a BMI ≥ 27 kg/m2 and ≥ 1 obesity complication [15, 19]. This classification differs from the Japanese definition, where obesity disease is defined as BMI ≥ 25 kg/m2 and ≥ 1 obesity complication, congruent with real‐world findings whereby the frequency of obesity complications in Japanese individuals with obesity disease increases categorically across BMI classifications above 25 kg/m2 [40]. This is attributed to differences in body composition and characteristics between Asian and non‐Asian populations with obesity [14]. Thus, JASSO guidelines for obesity management delineate not only body weight reduction, but also the improvement of comorbidities. Epidemiological data suggest that Asian populations have a higher risk for T2D and cardiovascular disease than non‐Asian populations across the continuum of BMI, making abdominal visceral fat accumulation a stronger predictor of obesity complications than BMI [41]. Although the availability of OMMs is expanding, most recently with the approval of semaglutide and tirzepatide in Japan, there remains a substantial need for therapeutic options that can induce greater and more clinically meaningful weight reduction, as well as improve outcomes for patients with obesity complications across the BMI continuum. SYNCHRONIZE‐1 and ‐2 are 76‐week, multinational, randomised, double‐blind, placebo‐controlled, phase 3 clinical trials evaluating the efficacy and safety of survodutide as an adjunct to a reduced‐calorie diet and increased physical activity to reduce body weight in people with obesity without and with T2D, respectively. SYNCHRONIZE‐JP will provide important data on the efficacy, safety and tolerability of survodutide in participants with obesity disease in Japan; whereas SYNCHRONIZE‐1 enrolled participants with ≥ 1 obesity complication for those with BMI ≥ 27 kg/m2 without T2D, and SYNCHRONIZE‐2 enrolled participants with T2D only, the study design of SYNCHRONIZE‐JP will allow for the evaluation of participants with obesity complications across T2D, hypertension and dyslipidaemia. The efficacy endpoints in SYNCHRONIZE‐JP align with the concept of obesity disease in the JASSO guidelines and will not only assess the effects of survodutide on body weight reduction, but also analyse improvements in obesity complications. Specifically, the trial will provide crucial cardiometabolic and liver parameter data related to hypertension, dyslipidaemia, T2D and MASLD during body weight reduction. The BMI threshold used by JASSO to define obesity disease aligns with the observation of higher visceral adiposity in East Asian populations at lower BMI levels compared with other populations, which in turn contributes to the adverse metabolic outcomes of lipotoxicity and suboptimal glycaemic control [11, 13, 42]. The stratification of participants by T2D diagnosis at baseline will provide important efficacy and safety data on survodutide with a focus on the population living with obesity disease and T2D. In the T2D population, targeting underlying obesity by achieving sustained body weight reduction ≥ 5% may substantially improve glycaemic control, reduce the need for glucose‐lowering medications, and improve cardiometabolic health [43]. The prevalence of T2D, dyslipidaemia and hypertension among enrolled participants in SYNCHRONIZE‐JP is consistent with real‐world estimates of the three most prevalent obesity complications in people with BMI ≥ 25 kg/m2 in Japan [44]. The secondary findings of glycaemic, lipid, and blood pressure profiles from SYNCHRONIZE‐JP will offer supporting evidence of the potential applications of survodutide among individuals with obesity disease and the respective obesity complications of T2D, dyslipidaemia, and hypertension. Similarly, MASLD is an established obesity complication in this population, both epidemiologically as well as observed in the SYNCHRONIZE‐JP baseline data. The benefits of survodutide for people with MASH have been described in a phase 2 trial, in which survodutide 6.0 mg for 48 weeks demonstrated a 62.0% reduction of liver fat content with significant histological improvement in MASH without worsening of fibrosis [25]. Both the findings from the SYNCHRONIZE‐JP MRI‐PDFF substudy and the ongoing multinational phase 3 clinical trial SYNCHRONIZE‐MASLD [38] will investigate people with overweight and obesity and presumed or confirmed MASH, thus expanding the evidence base on survodutide with regards to liver health in the clinical context of obesity [38]. In the SYNCHRONIZE‐JP MRI substudy, the evaluation of changes in body composition during weight reduction was incorporated into the design. Participants will be evaluated for total fat volume, visceral fat volume, subcutaneous fat volume, lean body volume, and contractile thigh muscle volume, the last of which was not assessed in SYNCHRONIZE‐1 or ‐2. Conventional weight‐based metrics such as BMI thresholds represent broad and variable classifications of obesity risk that do not differentiate between fat distribution and muscle mass in total body weight [45, 46]. The use of body composition parameters will allow for a broader understanding, not only in terms of weight reduction, but also the physiological and metabolic benefits associated with survodutide treatment including the impact of weight reduction on lean body mass. These analyses will be of interest given the high risk for sarcopenic obesity in Japan, and particularly in elderly people within this demographic, in assessing weight reduction by the quality and quantity of fat and muscle mass changes [47]. The eligibility criteria in SYNCHRONIZE‐JP are consistent with those in the STEP 6 phase 3 clinical trial that investigated the effects of semaglutide on body weight reduction in Japanese and South Korean participants [48]. The SURMOUNT‐J trial, which investigated the effects of tirzepatide on body weight reduction in Japanese individuals, enrolled participants with distinct obesity complications, namely, impaired glucose tolerance, hyperlipidaemia defined as fasting triglycerides ≥ 150 mg/dL, and MASLD [49]. Across SYNCHRONIZE‐JP, STEP 6 and SURMOUNT‐J, eligible participants included adults in Japan with a BMI ≥ 35 kg/m2 with ≥ 1 obesity complication, or a BMI of ≥ 27 kg/m2 with ≥ 2 obesity complications. The baseline characteristics of the trial populations enrolled in SYNCHRONIZE‐JP, STEP 6 and SURMOUNT‐J are shown in Table S1. The mean age, body weight and BMI of participants were similar across those three trials. The required obesity complications for study enrolment were consistent between SYNCHRONIZE‐JP and STEP 6, with a similar proportion of participants with T2D (24.1% vs. 25%), hypertension (72.6% vs. 75%) and dyslipidaemia (81.4% vs. 86%). This study has some limitations. The trial period of 76 weeks may limit the long‐term generalisability of the prospective efficacy and safety data. The protocol's exclusion criteria, such as concomitant medications or severe complications or conditions—including history of recent cardiovascular events—may also limit the generalisability of the results in real‐world practice among the wider population of people with obesity disease. These limitations will be at least partially addressed by the ongoing SYNCHRONIZE‐CVOT phase 3 trial, which will elucidate the clinical benefits of survodutide in populations with overweight and obesity and with established cardiovascular disease or chronic kidney disease, and will provide long‐term safety and efficacy data [36]. Crucially, the results of SYNCHRONIZE‐JP should be interpreted against that of the wider SYNCHRONIZE phase 3 trial programme to allow for a comprehensive and clinically meaningful understanding of the therapeutic profile of survodutide. Conclusions The SYNCHRONIZE phase 3 clinical development programme is evaluating the efficacy, safety, and tolerability of survodutide for the management of obesity disease in adults with and without T2D. SYNCHRONIZE‐JP was designed based on the Japanese definition of obesity disease and clinical practice guidelines, a long‐established framework that has supported clinical research and regulatory approval of anti‐obesity therapies in Japan [50]. This trial will contribute important data on the efficacy and safety of survodutide in people with obesity disease or high‐degree obesity disease in Japan. Author Contributions K.Y., T.Y., Y.F., Y.T., W.O., M.K., S.Y., T.I., L.B. and M.B. were involved in the design and planning of the study. S.Y. was involved in the statistical analyses. All authors contributed to developing the draft, critically reviewed and edited it, and approved the final version of the manuscript. The authors meet criteria for authorship as recommended by the ICMJE, were fully responsible for all content and editorial decisions, and were involved at all stages of manuscript development. Funding The study was supported and funded by Boehringer Ingelheim. Conflicts of Interest K.Y. reports scholarship donations from Nippon Boehringer Ingelheim Co. Ltd., Sumitomo Pharma Co. Ltd., Mitsubishi Tanabe Pharma Corporation and Takeda Pharmaceutical Co. Ltd.; and has received honoraria from Astellas Pharma Inc., Kowa Company Ltd., Sanofi K.K., Sumitomo Pharma Co. Ltd., Daiichi Sankyo Company Ltd., Taisho Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Nippon Boehringer Ingelheim Co. Ltd., Novartis Pharma K.K., Novo Nordisk Pharma Ltd., Bayer Yakuhin Ltd. and Eli Lilly Japan K.K. T.Y. reports speaker fees/honoraria from MSD K.K., Sumitomo Pharma Co. Ltd., Teijin Pharma Ltd., Nippon Boehringer Ingelheim Co. Ltd., Novo Nordisk Pharma Ltd., Eli Lilly Japan K.K. and Mitsubishi Tanabe Pharma Corporation; scholarship donations from Sumitomo Pharma Co. Ltd. and Mitsubishi Tanabe Pharma Corporation; research funding from Kowa Company Ltd., Nipro Co., Nitto Boseki Co. Ltd. and MedMirai Inc.; and course funding from Novo Nordisk Pharma Ltd., Nippon Boehringer Ingelheim Co. Ltd., Kowa Company Ltd., Nitto Boseki Co. Ltd. and Asahi Mutual Life Insurance Co. Y.F. reports no competing interests. Y.T. reports no competing interests. M.K., S.Y., T.I., L.B. and M.B. are employees of Boehringer Ingelheim. W.O. reports scholarship donations from Sumitomo Pharma Co. Ltd.; research funding from Noster Inc., Nippon Boehringer Ingelheim Co. Ltd., Eli Lilly Japan K.K., Sumitomo Pharma Co. Ltd. and Novo Nordisk Pharma Ltd.; and has received honoraria from Sumitomo Pharma Co. Ltd., Abbott Japan LLC, Nippon Boehringer Ingelheim Co. Ltd., Novo Nordisk Pharma Ltd. and Eli Lilly Japan K.K. Supporting information Data S1: dom70862‐sup‐0001‐Supinfo.docx. Acknowledgements Survodutide is licensed to Boehringer Ingelheim from Zealand Pharma, with Boehringer solely responsible for development and commercialisation globally. The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE) as supported by Good Publication Practice (GPP) guidelines. The authors did not receive payment related to the development of this manuscript. Boehringer Ingelheim was given the opportunity to review the manuscript for medical and scientific accuracy, as well as intellectual property considerations. Jia Gao, PharmD, of Envision Ignite, an Envision Medical Communications agency, a part of Envision Pharma Group, provided medical writing support, which was contracted and funded by Boehringer Ingelheim. Yokote K., Yamauchi T., Fukushima Y., et al., “Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE‐JP Trial,” Diabetes, Obesity and Metabolism 28, no. 8 (2026): 6595–6606, 10.1111/dom.70862. Handling Editor: Richard Donnelly This work was previously presented at the 46th Annual Meeting of the Japan Society for the Study of Obesity (JASSO), 4th October 2025. Data Availability Statement To ensure independent interpretation of clinical study results and enable authors to fulfil their role and obligations under the ICMJE criteria, Boehringer Ingelheim grants all external authors access to relevant clinical study data. In adherence with the Boehringer Ingelheim Policy on Transparency and Publication of Clinical Study Data, scientific and medical researchers can request access to clinical study data, typically 1 year after the approval has been granted by major Regulatory Authorities or after termination of the development programme. Researchers should use the https://vivli.org/ link to request access to study data and visit https://www.mystudywindow.com/msw/datasharing for further information. References Associated Data Supplementary Materials Data S1: dom70862‐sup‐0001‐Supinfo.docx. Data Availability Statement To ensure independent interpretation of clinical study results and enable authors to fulfil their role and obligations under the ICMJE criteria, Boehringer Ingelheim grants all external authors access to relevant clinical study data. In adherence with the Boehringer Ingelheim Policy on Transparency and Publication of Clinical Study Data, scientific and medical researchers can request access to clinical study data, typically 1 year after the approval has been granted by major Regulatory Authorities or after termination of the development programme. Researchers should use the https://vivli.org/ link to request access to study data and visit https://www.mystudywindow.com/msw/datasharing for further information.